Investigational drug · Phase 2
Intracerebroventricular of MT027 UCAR-T Cell targeting B7H3
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Brain Metastases From Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Intracerebroventricular of MT027 UCAR-T Cell targeting B7H3"
First trial start
2026
Nov 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Intracerebroventricular of MT027 UCAR-T Cell targeting B7H3", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Brain Metastases From Solid Tumors
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Intracerebroventricular of MT027 UCAR-T Cell targeting B7H3" as an intervention, largest first.
- The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent GliomaNot yet recruiting
T-MAXIMUM Pharmaceutical IncIndustry
NCT07386002 · 40 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 13, 2028
Drug: Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3 · For: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Sites: Baltimore, Maryland; Hualien City, Taiwan; Kaohsiung City, Taiwan · 4 sites in all
- The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid TumorsNot yet recruiting
T-MAXIMUM Pharmaceutical IncIndustry
NCT07897799 · 40 participants (planned) · Start Dec 30, 2027 · Primary completion Dec 20, 2029
Drug: Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3 · For: Brain Metastases From Solid Tumors
Sites: Houston, Texas; Taoyuan, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.